---
title: 'RNA methylation: where to from here for hematological malignancies?'
date: '2024-12-08'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39647657/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241209184155&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: RNA methylation and the machinery that regulates or 'reads' its expression
  has recently been implicated in the pathogenesis of acute myeloid leukemia (AML)
  and other hematological malignancies. Modulation of these epigenetic marks has started
  to become a reality as several companies around the world seek to leverage this
  knowledge therapeutically in the clinic. While the bases of observed activity in
  AML have been described by numerous groups, the exact context in which these therapies
  ...
disable_comments: true
---
RNA methylation and the machinery that regulates or 'reads' its expression has recently been implicated in the pathogenesis of acute myeloid leukemia (AML) and other hematological malignancies. Modulation of these epigenetic marks has started to become a reality as several companies around the world seek to leverage this knowledge therapeutically in the clinic. While the bases of observed activity in AML have been described by numerous groups, the exact context in which these therapies ...